Umoja Biopharma Analysis: $363M Raised
What is Umoja Biopharma?
In vivo CAR T cell therapy developer
HQ Country
Seattle, United States
Employees
1-10
Founded
2019
HQ State/Province
Washington
Funding Category
Series C
HQ Full Address
1616, Seattle, Washington 98102, United States
Product Features & Capabilities
- VivoVec platform for in vivo CAR T cell therapies
- In-house manufacturing capabilities for CAR T therapeutics
Other Considerations
Received FDA Fast Track Designation for UB-VV111; Raised $100 million in Series C financing; Named one of 2025's Most Promising Biotech Companies by Endpoints News and Fierce Biotech
